COVID-19

Cognitive rehabilitation significantly improved goal attainment and satisfaction in adults with long COVID-related cognitive impairment.

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

NCCN added pemivibart to its lymphoma guidelines, expanding COVID-19 prevention options for immunocompromised patients.

New wastewater data and prior research suggest COVID-19 may follow recurring spring and summer transmission patterns, unlike influenza and RSV.

A new study finds 2024-2025 COVID-19 vaccines reduced hospitalization and critical illness risk among adults, although protection waned over time.

The FDA approved a supplemental BLA for Organon's tocilizumab biosimilar Tofidence.

Learn how the Cicada COVID-19 variant spreads, common symptoms, who may be at risk, and what precautions experts recommend.

Jerry A. Krishnan, MD, PhD, discusses NIH RECOVER findings on long COVID, pulmonary complications, and immune dysfunction at ATS 2026.

Nirmatrelvir-ritonavir was most likely to be cost-effective among adults aged 18 to 64 years with comorbidities, particularly those with lung disease or immune disorders.

Muhammad Bilal Abid, MD, discusses COVID prevention gaps, monoclonal antibodies, and infection risk in immunocompromised patients with CLL.

Wastewater SARS-CoV-2 levels correlated with hospital COVID-19 cases, supporting targeted screening of asymptomatic patients.

Phase 3 CANOPY data show pemivibart safely prevented COVID-19 in patients with CLL, supporting EUA use for immunocompromised populations.

JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long COVID risk and symptom severity.

A study of 46 million visits finds telemedicine remains above prepandemic levels, but older adults and minority groups are less likely to use virtual care.

Experts examine evolving long COVID definitions, risk factors, diagnosis challenges, vaccine impact, and workforce effects.

Kevin Ma, PhD, discusses new data showing 2024–2025 COVID-19 vaccines reduced hospitalization and severe outcomes.

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants.

The postpandemic reinstatement of Medicare’s 3-day rule lengthened hospital stays without affecting SNF use, spending, or short-term outcomes, raising questions about its value.

Nursing home capacity has declined since the COVID-19 pandemic, causing greater strain on postacute care, especially in rural areas.

Economic stability and social factors significantly influence the risk of pediatric long COVID, highlighting the need for targeted health interventions.

COVID-19 vaccination during pregnancy lowers hospitalization and preterm birth risks, providing key guidance for maternal care strategies.

School reopenings after COVID-19 closures significantly improved children's mental health, reducing diagnoses of depression, anxiety, and ADHD.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

COVID-19 vaccination before infection lowered long COVID risk in adolescents, highlighting vaccines as an effective prevention strategy.

COVID-19–related work absences remain elevated post pandemic, especially in high-exposure jobs, highlighting lasting labor market impacts.